Tanaka et al. recently showed that the Lung Immune Prognostic Index (LIPI) could predict resistance to ICI in patients with previously treated advanced NSCLC, finding that in patients with low PD-L1 treated with chemoimmunotherapy (N = 237), LIPI can especially predict both PFS (HR, 2.75; p < 0.001) and OS (HR, 2.01; 95% CI, 1.28–3.15; p < 0.001) [48]. Here, CD274 is linked to non-small cell lung carcinoma.